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In microarray-based cancer classiﬁcation and prediction, gene selection is an important research problem owing to the large num-
ber of genes and the small number of experimental conditions. In this paper, we propose a Bayesian approach to gene selection and
classiﬁcation using the logistic regression model. The basic idea of our approach is in conjunction with a logistic regression model to
relate the gene expression with the class labels. We use Gibbs sampling and Markov chain Monte Carlo (MCMC) methods to dis-
cover important genes. To implement Gibbs Sampler and MCMC search, we derive a posterior distribution of selected genes given
the observed data. After the important genes are identiﬁed, the same logistic regression model is then used for cancer classiﬁcation
and prediction. Issues for eﬃcient implementation for the proposed method are discussed. The proposed method is evaluated against
several large microarray data sets, including hereditary breast cancer, small round blue-cell tumors, and acute leukemia. The results
show that the method can eﬀectively identify important genes consistent with the known biological ﬁndings while the accuracy of the
classiﬁcation is also high. Finally, the robustness and sensitivity properties of the proposed method are also investigated.
 2004 Elsevier Inc. All rights reserved.
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Cancer classiﬁcation and prediction has become one
of the most important applications of DNA microarray
due to their potentials in cancer diagnostic and prognos-
tic prediction [2,9,11,13]. Given the thousands of genes
and the small number of data samples involved in
microarray-based classiﬁcation, gene selection is an
important research problem [17]. Many gene selection
algorithms have been proposed in the literature for gene
classiﬁcation; for example, support vector machines [10],
genetic algorithms [16], Bayesian variable selection
[14,33–35], the minimum description length principle1532-0464/$ - see front matter  2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.jbi.2004.07.009
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E-mail address: stephen_wong@hms.harvard.edu (S.T.C. Wong).for model selection [12], and the logistic regression mod-
el [3]. The logistic regression model, also known as logit
in the literature, is one of the most common models for
prediction, regression, and classiﬁcation of disease data
[6,22].
Logit-based methods have been successfully applied
to cancer classiﬁcation [3,19]; nevertheless, gene selec-
tion and classiﬁcation based on the same logit method
does not exist. Certain variable selection schemes for
the logistic regression model have been proposed
[4,23], but they are not suitable for microarray-like
problems having large numbers of variables and small
sample sizes.
Our observation is that no closed form expression for
the posterior distribution of the selected genes exists
for logistic regression, whereas such a closed form
250 X. Zhou et al. / Journal of Biomedical Informatics 37 (2004) 249–259expression exists for linear probit regression [14]. Moti-
vated by the Bayesian variable selection based on probit
regression, we thus propose a new Bayesian method to
both gene selection and classiﬁcation using the logistic
regression model. The basic idea of our Bayesian meth-
od is in conjunction with a logistic regression model to
relate the gene expression with the class labels. Rather
than ﬁxing the number of selected genes or features,
we assign a prior distribution over it. The new Bayes-
ian-based logit method allows ﬂexibility compared to
the existing logit methods by adding pre-determined
constraints, such as reducing the selected number of
genes for consideration using a prior distribution. This
method uses Gibbs sampling and Markov chain Monte
Carlo (MCMC) algorithms to discover important genes.
To implement Gibbs Sampler or MCMC search, how-
ever, we need to derive a posterior distribution of the se-
lected genes given the observed data. Unfortunately, no
closed form of such a distribution exists for logistic
regression models. Thus, we adapt an approximated
posterior distribution in our calculation.
After the important genes are identiﬁed, the same
Bayesian-based logit method in turn will be used for
cancer classiﬁcation and prediction. We have evaluated
the proposed method against several published micro-
array disease data sets, including those of hereditary
breast cancer, small round blue-cell tumors, and acute
leukemia. The experimental results show that the pro-
posed Bayesian method can eﬀectively identify impor-
tant genes consistent with the known biological
ﬁndings while the accuracy of the classiﬁcation is high.
In addition, the robustness and sensitivity properties
for the Bayesian-based logit method are also
investigated.
The remainder of this paper is organized as follows.
In Section 2, we ﬁrst formulate the problem of gene
selection and classiﬁcation for logistic regression, then
we provide the Bayesian gene selection algorithm using
Gibbs sampling and MCMC algorithm. Section 3 pro-
vides experimental results on the three diﬀerent micro-
array data sets. Section 4 presents the conclusions.
Finally, the detailed derivation of the proposed Bayes-
ian-based logical regression method and certain proce-
dures for eﬃcient implementation of the proposed
Bayesian method are discussed in Appendices A and B.2. Material and methods
2.1. Material preparation for DNA microarray
DNA microarrays work by hybridization of labeled
RNA or DNA in solution to DNA molecules attached
at speciﬁc locations on a surface. Such arrays are often
made of high-density arrays of oligonucleotide [18] or
complementary DNA (cDNA) [25,26]. Such an arrange-ment allows a highly parallel monitoring of gene expres-
sion (mRNA abundance) patterns for thousands of
genes at the same time in a single experiment. These
transcription proﬁling techniques have been applied to
study the patterns of gene expression across many exper-
iments that survey a wide variety of cellular responses,
phenotypes, conditions, and often through observations
at multiple time points [7,15,18,21,25,28,29,31]. Such
studies often involve two major objectives, class discover
and class prediction, which can be used to develop a
more complete understanding of the function, regula-
tion, and interactions of genes and their products at
RNA and protein levels. The more comprehensive
knowledge may then help to delineate the underlying eti-
ology of many diseases and improve their diagnosis and
prognosis [9,11,13]. Further details of experimental pro-
cedures in sample preparation, hybridization, and wash-
ing, are documented in the above mentioned references.2.2. Problem formulation
Assume we are interested in classifying whether a par-
ticular cancer is present or not. Let z = [z1, . . . ,zm]
T de-
note the class labels, where zi = 1 indicates sample i has
the cancer, and zi = 0 indicates sample i does not have
the cancer. Denote x1, . . . ,xn as the expression levels
of n genes. Let xi, j be the measurement of the expression
level of the jth gene for the ith sample. Let X = (xi, j)m, n
denote the expression levels of all genes, i.e.,
X ¼
x1;1 x1;2    x1;n
x2;1 x2;2    x2;n
..
. ..
. . .
. ..
.
xm;1 xm;2    xm;n
2
66664
3
77775: ð1Þ
Let Xi , [xi, 1,xi, 2, . . . ,xi, n] denote the ith row of
the above matrix. We model mi , P(zi = 1|X) by using
a logistic regression model given by
log
mi
1 mi ¼X ib, xi;1b1þ    þ xi;nbn; i¼ 1; . . . ;m; ð2Þ
where b , [b1, . . . ,bn]T contains the regression coeﬃ-
cients. According to [1,20], the logistical model can be
rewritten as zi = 1(yi > 0), yi = Xib + log(F (ti)/(1  F
(ti))), ti Nð0; r2Þ, and r2  C (m/2,m/2), where F denotes
the cumulative distribution function of the t distribution
with mean 0 and variance 1. This model can be approxi-
mated by [20] zi = 1(yi > 0), yijb; r2 NðX ib; ar2I mÞ,
r2  C (m/2,m/2), where a , p2 (m  2)/3m with m = 7.3 and
I is an identitymatrix or unit matrix. Then posterior com-
putation for parameters b, r2 under that approximation
can be accomplished usingMCMC algorithm.Motivated
by this, we derived approximated posterior distributionof
a indicator vector for gene selection.
Deﬁne c as the n · 1 indicator vector with the jth
element cj such that cj = 0 if bj = 0 (the variable is not
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Bayesian variable selection is to estimate c from the pos-
terior distribution p (c|y,X). Given c, let bc consists of all
non-zero elements of b and let Xc be the columns of X
corresponding to those c that are equal to 1. Now the
problem is how to estimate c and the corresponding
bc. Note that no closed form expression exists for the
posterior distribution p (b|c,y,X), and neither for
p (c|y,X).
2.3. Bayesian gene selection based on logistic regression
The indicator vector c can be modeled as a realization
from any prior p (c) on the 2n possible values of c given
by pðcÞ ¼ Qni¼1pcii ð1 piÞð1ciÞ, where pi = P (ci = 1) is a
prior probability to select the jth gene. This form is actu-
ally a Bernoulli distribution for selecting each gene.
We make the following assumptions on the priors of
the parameters. First, given bc, Xc, and r
2, the likelihood
of yjbc;Xc; r2 NðXcbc; ar2IÞ. Then, given c and r2,
the prior for bc is bc Nð0; r2RcÞ, where Rc is set as
ðXTcXcÞ1 in this study. Given c, the prior of r2 is as-
sumed to be an conjugate inverse-Gamma distribution
pðr2jcÞ / IGðm
2
; m
2
Þ. Moreover, the fcjgnj¼1 are assumed
to be independent with p (cj = 1) = pj, j = 1,. . .,n. In this
paper we set pj = 15/n for all genes, based on the total
sample number m = 22. If pj is chosen to take a larger
value, then we found that often times ðXTcXcÞ1 is
singular.
Here we introduce the Bayesian variable selection
principle [5]. A Gibbs sampler is employed to estimate
the parameters. Denote
Sðc; yÞ,mþ a1yTP cy; ð3Þ
where y = [y1,y2, . . . ,ym]
T, P c,I XcM cXTc with
M c,ðXTcXc þ aR1c Þ1 ¼ ð1þ aÞ1ðXTcXcÞ1. Deﬁne
nc ¼
Pn
i¼1ci. In Appendix A, we show that
pðyjcÞ /
Z
r
Z
bc
pðyjbc; r2Þpðbcjr2ÞdpðbcÞ
( )
pðr2Þdr2
/ amþnc2 ð1þ aÞ
nc
2 Sðc; yÞmþm2 : ð4Þ
Then the posterior distribution of c is
pðcjyÞ / pðyjcÞpðcÞ
/ amþnc2 ð1þ aÞ
nc
2 Sðc; yÞmþm2
Yn
j¼1
p
cj
j ð1 pjÞ1cj :
ð5Þ
In Appendix A, we also show the posterior distribution
of r2 and b are, respectively, given by
pðr2jy;XcÞ / IG mþ m ; Sðc; yÞ
 
; ð6Þ
2 2pðbjy;Xc; r2Þ /NðH c; ar2M cÞ; ð7Þ
where H c ,M cXTc y ¼ ð1þ aÞ1ðXTcXcÞ1XTc y. Based on
the posterior distribution (5), a Gibbs sampler can be
employed to estimate all the parameters. We use the
following Gibbs sampling algorithm to estimate
{c,bc,r
2}.
 Draw c from p(c|y) in (5). In fact, we sample each cj
independently from
pðcjjy; ci6¼jÞ / a
mþnc
2 ð1þ aÞ
nc
2 Sðc; yÞmþm2 pcjj ð1 pjÞ1cj ;
j ¼ 1; . . . ; n: ð8Þ
 Draw r2 from p(r2|y,c) in (6).
 Draw b from p(b|c,y) in (7).
 Draw zi, i = 1, . . . ,m from a truncated normal distri-
bution as follows [24]: yijb; zi ¼ 1 NðX ib; ar2Þ
1fyi>0g, yijb; zi ¼ 0 NðX ib; ar2Þ1fyi<0g.
In this study, 25,000 Gibbs iterations are imple-
mented with the ﬁrst 5000 as burn-in period. We obtain
the Monte Carlo samples as {c(t), t = 1, . . . ,T}, where
T = 25,000. Finally, we count the number of times that
each gene appears in {c(t), t = 5001, . . . , 25,000}. We de-
ﬁne the appearance frequency of a gene as the number of
appearances of this gene divided by the total iteration
(i.e., 20,000 here). The genes with the highest appear-
ance frequencies play the strongest role in predicting
the target gene. We will discuss some implementation is-
sues in the Appendix B.
2.4. Cancer classiﬁcation and prediction using the stron-
gest genes
Now assume the genes corresponding to non-zero c
are the strongest genes obtained by the above Bayesian
variable-selection algorithm. We still use Xc to denote
the proﬁles of these strongest genes. For ﬁxed c, we
again use a Gibbs sampler to estimate the linear regres-
sion coeﬃcients b as follows: First draw bc according to
(7), then draw r2 according to (6) and iterate the two
steps. In this study, 1500 iterations are implemented
with the ﬁrst 500 as the burn-in period. Thus we obtain
the Monte Carlo samples f~bðtÞc ; ~r2
ðtÞ
; t ¼ 1; . . . ; ~Tg. We
then predict the tested sample by Pðy ¼ 1jX cÞ ¼
1
~T
P~T
t¼1 expfX c~b
ðtÞ
c g=ð1þ expfX c~b
ðtÞ
c gÞ. If we consider
computational complexity, an alternative approach is
iterative methods such as the Newton–Raphson proce-
dure which can be adopted to obtain the maximum like-
lihood estimate of bc [8], then we can predict the tested
sample by
P ðy ¼ 1jX cÞ ¼
expfX cbcg
1þ expfX cbcg
: ð9Þ
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If there are 3000 gene variables, then for each itera-
tion we have to estimate bc 3000 times because we need
to sample cj for each gene according to (8). The compu-
tational complexity of the Bayesian gene selection algo-
rithm in the previous section is very high. Hence, some
fast algorithms must be developed to speed up the com-
putation. Here we pre-select some genes using the fol-
lowing procedure. The other fast implementation
issues are discussed in Appendix B.
Suppose that the total number of genes is p, and we
will only consider n < p candidates in the Bayesian selec-
tion algorithm. We next discuss how to pre-select the n
genes using an F-test. In pattern recognition, we usually
adopt the following criterion: the smaller is the sum of
squares within groups and the bigger is the sum of
squares between groups, then it is expected a better clas-
siﬁcation accuracy. Therefore we can deﬁne a score
using the above two statistics to pre-select genes, i.e.,
the ratio of the between-group to within-group sum of
squares:
RðjÞ,
Pm
i¼1
PK1
k¼0 1ðyi¼kÞðxk;j  xjÞ2Pm
i¼1
PK1
k¼0 1ðyi¼kÞðxi;j  xk;jÞ2
; 1 6 j 6 p; ð10Þ
where K the number of classes; p is the total number of
original genes (Note that the number of genes n used in
the Bayesian selection procedure is much smaller than
p); xj denotes the average expression level of gene j
across all samples; and xk;j denotes the average expres-
sion level of gene j across the samples belonging to class
k where class k corresponds to {yi = k}; and the indica-
tor function 1X is equal to one if event X is true and zeroTable 1
The top 20 important genes using the proposed gene selection algorithm for
Gene No. Frequency Index No. (Clone ID) Gen
1 0.3103 10 (26184) Pho
2 0.1621 118 (47542) Sma
3 0.1399 336 (823940) Tran
4 0.1338 2699 (44180) a-2-
5 0.1335 2761 (47884) Mac
6 0.1330 742 (183200) Fum
7 0.1305 2382 (21652) Cate
8 0.1289 2018 (139354) EST
9 0.1279 157 (809981) Glut
10 0.1260 739 (214068) GAT
11 0.1260 1120 (841617) Hum
12 0.1251 2272 (309583) EST
13 0.1250 1620 (137638) EST
14 0.1246 1999 (247818) EST
15 0.1243 1859 (307843) EST
16 0.1241 439 (160793) Disc
17 0.1234 2734 (46019) Min
18 0.1233 247 (725680) Tran
19 0.1233 3009 (366647) Buty
20 0.1230 2423 (26082) Butyotherwise. We select a threshold @ and keep those genes j
such that RðjÞP @. The pre-selection procedure yields n
genes such that RðjÞP @.3. Experimental results
3.1. Breast cancer data
In our ﬁrst experiment, we will focus on hereditary
breast cancer data, which can be downloaded from the
web page for the original paper [11]. In [11], cDNA
microarrays are used in conjunction with classiﬁcation
algorithms to show the feasibility of using diﬀerences
in global gene expression proﬁles to separate BRCA1
and BRCA2 mutation-positive breast cancers. Twenty-
two breast tumor samples from 21 patients were exam-
ined: 7 BRCA1, 8 BRCA2, and 7 sporadic. There are
3226 genes for each tumor sample. We use our methods
to classify BRCA1, BRCA2, and sporadic. The ratio
data have been truncated from below at 0.1 and above
at 20. Log of the ratio data are employed to test the
proposed gene selection method. The cross-validation
(leave-one-out) method is employed to compute all clas-
siﬁcation errors in this paper. The number of preselected
genes are 473 in this data set.
Table 1 lists the strongest genes using the proposed
approximate Bayesian gene selection method. Gene 10
(Clone ID: 26184, phosphofructokinase, platelet) is the
strongest gene. The gene TOB1 (Clone ID 823940) is
the top 3 gene listed in Table 1 [14]. Gene 1008 (Clone
ID: 897781, keratin 8) is also listed in the top 20 genes.
These results are consistent with other references [11].breast cancer data (pi = 15/n)
e description
sphofructokinase, platelet
ll nuclear ribonucleoprotein D1 polypeptide (16kD)
sducer of ERBB2, 1 (TOB1)
macroglobulin
rophage migration inhibitory factor (glycosylation-inhibiting factor)
arylacetoacetate
nin (cadherin-associated protein), a1 (102 kDa)
s
athione peroxidase 4 (phospholipid hydroperoxidase)
A-binding protein 3
an mRNA for ornithine decarboxylase antizyme, ORF 1 and ORF 2
s
s
s
s
s, large (Drosophila) homolog 1
ichromosome maintenance deﬁcient (S. cerevisiae) 7
scription factor AP-2c (activating enhancer-binding protein 2c)
rate response factor 1 (EGF-response factor 1)
rate response factor 1 (EGF-response factor 1)
Table 4
The estimated probabilities of each sample for SRBCT data using the
proposed algorithm (pi = 15/n)
Sample index No. True label P(y = 1|X) Prediction
1 0 0.0000 0
2 0 0.0001 0
3 0 0.0001 0
4 0 0.0000 0
5 0 0.0000 0
6 0 0.0000 0
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is seen that the classiﬁcation error based 5 genes and 10
genes is zero. Note that there is one error in the original
paper [11]. There is one error using 15 genes, which is
likely due to the small sample size. The conditional
probabilities based the three criteria using top 10 genes
are listed in Table 2. These are very close to the true la-
bel values (namely, 0 and 1). The Eq. (9) is employed to
predict cancers in this study.Table 2
The estimated probabilities of each sample for breast cancer data using
the proposed Bayesian gene algorithm (pi = 15/n)
Sample index No. True label P (y = 1|X) Prediction
1 0 0.0060 0
2 0 0.0000 0
3 0 0.0000 0
4 0 0.0021 0
5 0 0.0000 0
6 0 0.0237 0
7 1 1.0000 1
8 1 0.9709 1
9 1 1.0000 1
10 1 1.0000 1
11 1 0.9915 1
12 1 1.0000 1
13 1 1.0000 1
14 1 1.0000 1
15 1 0.9999 1
16 1 0.9908 1
17 1 0.9359 1
18 0 0.0000 0
19 1 1.0000 1
20 1 1.0000 1
21 1 1.0000 1
22 1 1.0000 1
No. of misclassiﬁcation 0
Table 3
The top 20 important genes selected using the proposed Bayesian gene selection algorithm for SRBCT data (pi = 15/n)
Gene No. Frequency Index No. (Clone ID) Gene description
1 0.1403 1389 (770394) Fc fragment of IgG, receptor, transporter, a
2 0.1310 52 (50359) Mannose phosphate isomerase
3 0.1250 1873 (166195) Ribonuclease/angiogenin inhibitor
4 0.1240 1914 (824704) Mannose phosphate isomerase
5 0.1195 545 (1435862) Antigen identiﬁed by monoclonal antibodies 12E7, F21 and O13
6 0.1138 842 (262231) No name
7 0.1128 1093 (812965) v-myc avian myelocytomatosis viral oncogene homolog
8 0.1108 246 (377461) Caveolin 1, caveolae protein, 22kD
9 0.1105 812 (166236) Glucose-6-phosphate dehydrogenase
10 0.1088 153 (383188) Recoverin
11 0.1050 137 (486175) Solute carrier family 16 (monocarboxylic acid transporters), member 1
12 0.1000 2157 (244637) Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 45620
13 0.0995 1088 (85171) ADP-ribosylation factor 4
14 0.0985 2050 (295985) ESTs
15 0.0985 976 (786084) Chromobox homolog 1 (Drosophila HP1 b)
16 0.0985 742 (812105) Transmembrane protein
17 0.0978 1601 (629896) Microtubule-associated protein 1B
18 0.0960 823 (134748) Glycine cleavage system protein H (aminomethyl carrier)
19 0.0933 255 (325182) Cadherin 2, N-cadherin (neuronal)
20 0.0922 1862 (789376) Thioredoxin reductase 1
7 0 0.0000 0
8 0 0.0000 0
9 0 0.0000 0
10 0 0.0060 0
11 0 0.0032 0
12 0 0.0025 0
13 0 0.0000 0
14 0 0.0000 0
15 0 0.0115 0
16 0 0.0000 0
17 0 0.0001 0
18 0 0.0001 0
19 0 0.0000 0
20 0 0.0000 0
21 0 0.0042 0
22 0 0.0002 0
23 0 0.0002 0
24 1 0.9928 1
25 1 1.0000 1
26 1 0.9954 1
27 1 1.0000 1
28 1 1.0000 1
29 1 1.0000 1
30 1 1.0000 1
31 1 1.0000 1
32 1 1.0000 1
33 1 1.0000 1
34 1 1.0000 1
35 1 0.9999 1
No. of misclassiﬁcation 0
Table 6
The estimated probabilities of each sample for leukemia data using the
proposed algorithm (pi = 15/n)
Sample index No. True label P (y = 1|X) Prediction
1 0 0.0006 0
2 0 0.0004 0
3 0 0.0000 0
4 0 0.0000 0
5 0 0.0000 0
6 0 0.0000 0
7 0 0.0000 0
8 0 0.0000 0
9 0 0.0000 0
10 0 0.0000 0
11 0 0.0000 0
12 0 0.0006 0
13 0 0.0000 0
14 0 0.0007 0
15 0 0.0000 0
16 0 0.0000 0
17 0 0.0025 0
18 0 0.0005 0
19 0 0.0000 0
20 0 0.0000 0
21 0 0.0010 0
22 0 0.0007 0
23 0 0.0029 0
24 0 0.0000 0
25 0 0.0001 0
26 0 0.0000 0
27 0 0.0000 0
28 1 0.9963 1
29 1 0.9992 1
30 1 1.0000 1
31 1 1.0000 1
32 1 0.9931 1
33 1 0.9935 1
34 1 1.0000 1
35 1 1.0000 1
36 1 0.9999 1
37 1 1.0000 1
38 1 1.0000 1
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This experiment focuses on the small, round blue cell
tumors (SRBCTs) of childhood, which include neuro-
blastoma (NB), rhabdomyosarcoma (RMS), non-hodg-
kin lymphoma (NHL), and the Ewing family of tumors
(EWS) in [13]. We classify the rhabdomyosarcoma and
neuroblastoma tumors. The data set for the two cancers
is composed of 2308 genes, and the sample consists of 35
tumors, 23 for RMS, and 12 for NB. The ratio data has
been truncated from below at 0.01. The number of pres-
elected genes are 282 in this data set.
Table 3 lists the strongest genes using the proposed
approximate Bayesian gene selection method. Gene
1389 (clone ID 770394) is top important gene in the list.
It is also an important gene listed in [13]. A number of
other previously noted genes also appear [13,32]: gene
545 (Clone ID 1435862), gene 246 (Clone ID 377461),
gene 153 (Clone ID 383188), gene 2050 (Clone ID
295985), gene 742 (Clone ID 812105), gene 1601 (Clone
ID 629896), and gene 255 (clone ID 325182). The condi-
tional probabilities based the three criteria using top 10
genes are listed in Table 4. These conditional probabili-
ties are very close to the true label values. Using the top
5, 10, and 15 genes for classiﬁcation based on the three
criteria, no error is found.
3.3. Acute leukemia data
The leukemia data of [9] is publicly available the pa-
pers original website. The microarray data contains
7129 human genes, sampled from 72 cases of cancer,
of which 38 are of type B-cell ALL, 9 are of type T-cell
ALL, and 25 of type AML. The data are preprocessed
as recommended in [30]: gene values are truncated fromTable 5
The top 20 important genes selected using the proposed Bayesian gene selection algorithm for acute leukemia data (pi = 15/n)
Gene No. Frequency Index No. Gene description
1 0.1153 4211 Vascular endothelial growth factor receptor 1 precursor
2 0.1108 5772 C-myb gene extracted from Human (c-myb) gene, complete primary cds
3 0.1093 2354 CCND3 cyclin D3
4 0.1083 1144 SPTAN1 spectrin, a, non-erythrocytic 1 (a-fodrin)
5 0.1038 1928 Oncoprotein 18 (Op18) gene
6 0.1035 4167 ALDR1 aldehyde reductase 1 (low Km aldose reductase)
7 0.1027 804 Macmarcks
8 0.1008 6281 MYL1 myosin light chain (alkali)
9 0.1008 4398 DNMT DNA methyltransferase
10 0.1003 1630 Inducible protein mRNA
11 0.1000 1882 CST3 cystatin C (amyloid angiopathy and cerebral hemorrhage)
12 0.0983 1834 CD33 CD33 antigen (diﬀerentiation antigen)
13 0.0978 5501 TOP2B topoisomerase (DNA) II b (180 kDa)
14 0.0978 2348 ACADM acyl-coenzyme A dehydrogenase, C-4 to C-12 straight chain
15 0.0978 1120 SNRPN small nuclear ribonucleoprotein polypeptide N
16 0.0975 5039 LEPR leptin receptor
17 0.0970 6855 TCF3 transcription factor 3 (E2A immunoglobulin enhancer-binding factors E12/E47)
18 0.0963 6279 GB DEF = PTX3 gene promotor region
19 0.0958 3258 Phosphotyrosine independent ligand p62 for the Lck SH2 domain mRNA
20 0.0948 1704 ADA adenosine deaminase
No. of misclassiﬁcation 0
Table 8
The top 20 important genes selected using the proposed Bayesian gene
selection algorithm for breast cancer data with diﬀerent prior pi = 10/n
Gene No. Frequency Index No. Clone ID
1 0.1409 10 26184
2 0.1210 118 47542
3 0.0980 336 823940
4 0.0970 858 783729
5 0.0927 258 324210
6 0.0920 733 134748
7 0.0885 2699 44180
8 0.0870 2018 139354
9 0.0867 955 950682
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ratio of the maximum over the minimum less than 5 or
the diﬀerence between the maximum and the minimum
less than 500 are excluded; and ﬁnally the base-10 loga-
rithm is applied to the 3571 remaining genes. Here we
consider the 38-tumor sample, splitting it between
ALL (11) and AML (27). The number of preselected
genes are 356 in this data set.
Table 5 lists the 20 strongest genes based on the pro-
posed approximate Bayesian gene selection. The index
number is the Clone ID in this data set. The top ten
genes are gene 4211, gene 5772, gene 2354, gene 1144,
gene 1928, gene 4167, gene 804, gene 6281, gene 4398,
and gene 1630. Genes 5772, gene 1882, gene 1834, gene
1630, and gene 5772 are also listed in [9]. The condi-
tional probabilities based the three criteria using top
10 genes are listed in Table 6. Again we saw that these
conditional probabilities are very close to the true label
values. Using the top 5, 10, and 15 genes for classiﬁca-
tion, no error is found. We also test the 34 samples,
and one error is found, but there are four error in origi-
nal paper [9].10 0.0862 1417 825478
11 0.0850 1466 767817
12 0.0830 2428 26184
13 0.0820 1120 841617
14 0.0818 272 47681
15 0.0808 1859 307843
16 0.0808 1008 897781
17 0.0805 1200 811930
18 0.0800 116 754998
19 0.0798 955 950682
20 0.0795 1531 7118264. Sensitivity and robustness
To check the sensitivity and robustness of our algo-
rithms, we have added white Gaussian noise with diﬀer-
ent variances to the breast cancer data and re-applied
our algorithms to the contaminated data. The strongest
genes are listed in Table 7. It is seen gene 10 (phospho-
fructokinase, platelet) and gene 336 TOB1 remain veryTable 7
The top 20 important genes selected using the proposed Bayesian gene selecti
Gene No. r = 0.1 r = 0.2
Frequency Index No. (Clone ID) Frequency
1 0.1411 10 (26184) 0.1356
2 0.1273 118 (47542) 0.1213
3 0.0980 336 (823940) 0.1000
4 0.0920 955 (950682) 0.0940
5 0.0907 2699 (44180) 0.0935
6 0.0905 1443 (566887) 0.0927
7 0.0887 2428 (26184) 0.0922
8 0.0885 2259 (814270) 0.0887
9 0.00882 733 (134748) 0.0860
10 0.0882 585 (41356) 0.0855
11 0.0865 1179 (788721) 0.0845
12 0.0850 496 (376516) 0.0845
13 0.0845 3009 (366647) 0.0838
14 0.0845 1999 (247818) 0.0825
15 0.0845 1008 (897781) 0.0823
16 0.0843 3010 (366824) 0.0823
17 0.0843 2387 (22230) 0.0820
18 0.0838 2259 (814270) 0.0820
19 0.0830 258 (324210) 0.0810
20 0.0828 1766 (239958) 0.0800important for diﬀerent noise levels. The results indicate
that the proposed methods are not sensitive to the diﬀer-
ent noise levels.
To check the sensitivity to the prior distributions,
we have re-run the algorithms for pi = 10/n. According
to Table 8, most of the selected genes are the same as
the gene list in Table 1, hence it is seen that the pro-
posed gene selection method is robust to the prior
setting.on algorithm for breast cancer data for diﬀerent noise levels (pi = 15/n)
r = 0.5
Index No. (Clone ID) Frequency Index No. (Clone ID)
10 (26184) 0.1467 10 (26184)
118 (47542) 0.1315 118 (47542)
336 (823940) 0.0975 272 (47681)
2699 (44180) 0.0970 336 (823940)
955 (950682) 0.0943 258 (324210)
2428 (26184) 0.0920 2428 (26184)
858 (783729) 0.0910 733 (134748)
1179 (788721) 0.0907 858 (783729)
1443 (566887) 0.0902 1120 (841617)
585 (41356) 0.0895 1620 (137638)
1999 (247818) 0.0885 1443 (566887)
258 (324210) 0.0875 2734 (46019)
733 (134748) 0.0848 1446 (767817)
1466 (767817) 0.0848 1179 (788721)
1531 (711826) 0.0838 2699 (44180)
1120 (841617) 0.0835 809 (810899)
2734 (46019) 0.0810 556 (212198)
2423 (26082) 0.0808 496 (376516)
272 (47681) 0.0805 1008 (897781)
1008 (897781) 0.0805 1466 (767817)
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Various gene selection methods and classiﬁers for
cancer classiﬁcation have been proposed. In particular,
there is strong evidence that Bayesian gene selection is
eﬀective [14]. Regarding classiﬁcation, the linear probit
(LProbit) [14], and logistical regression with AIC (BIC
and MDL) gene selection [36] have proved eﬀective.
Using the breast-cancer data set, we will compare the
performance of these classiﬁers when used in conjunc-
tion with the previously proposed Bayesian gene-selec-
tion methods and the logistic method developed in this
paper. We summarize linear probit based and logistical
regression with AIC-based gene selection, along with the
corresponding classiﬁers.
Probit gene selection and classiﬁcation [14]: the rela-
tion between the class label yi and the gene expression
levels xi is modeled by using a probit regression model
which yields P (yi = 1|xi) = U(xib), i = 1, . . . ,m, where
b = (b1,b2, . . . ,bn)
T is the vector of regression parame-
ters and U is the standard normal cumulative distribu-
tion function. Gene selection based on probit
regression is similar to that of logistic regression using
Gibbs sampling. The diﬀerence is the posterior distribu-
tion of p (c|z), see [14]. After obtaining the strongest
genes, we can estimate P (y = 1|X) using Gibbs sampling
for the probit regression classiﬁer. The model of logisti-
cal regression with AIC-based gene selection and classi-
ﬁcation is similar to the model used in this paper. The
diﬀerence is that we approximated p (c|z) by using infor-
mation theory AIC criterion.
Table 9 lists the top 20 genes selected by probit
regression and logistic regression with AIC-based geneTable 9
The top 20 important genes selected using linear probit regression [14] and log
for breast cancer data
Gene No. Probit
Frequency Index No. (Clone ID
1 0.0860 1008 (897781 )
2 0.0840 336 (823940)
3 0.0780 10 (26184)
4 0.0750 1068 (840702)
5 0.0710 496 (376516)
6 0.0690 118 (47542)
7 0.0660 3009 (366647)
8 0.0660 585 (293104)
9 0.0620 523 (28012)
10 0.0610 556 (212198)
11 0.0590 1999 (247818)
12 0.0550 2423 (26082)
13 0.0540 498 (667598)
14 0.0520 140 (30093)
15 0.0510 1277 (73531)
16 0.0500 955 (950682)
17 0.0500 272 (47681)
18 0.0490 2734 (46019)
19 0.0490 1859 (307843)
20 0.0480 555 (548957)selection, respectively. Gene 10 (phosphofructokinase,
platelet) and gene 336 TOB1 are important genes for
all methods, and also quite a few genes are the same
for all methods. The misclassiﬁcation numbers using
the three classiﬁers (Logit, LProbit, and Logit-AIC)
for three gene selection methods (logit, probit, Logit-
AIC) with 5, 10, and 15 top genes are as follows: No er-
ror is found for all of the classiﬁers based on Small
Round Blue-cell Tumors and acute leukemia data, but
one error for all of the classiﬁers based on breast cancer
data. Therefore, we conclude that the proposed ap-
proach in this study is at least comparative with the
other two.5. Conclusion
In this work, we proposed a Bayesian approach to
gene selection using the logistic regression model. The
basic idea of our approach is in conjunction with a
logistic regression model to relate the gene expression
with the class labels. Rather than ﬁxing the number
of selected genes or features, we assigned a prior dis-
tribution over it. The approach creates additional
ﬂexibility by allowing the imposition of constraints,
such as not allowing the dimension to be too big
by using this prior. We use Gibbs sampling and
MCMC methods to discover important genes. In or-
der to implement Gibbs Sampler and MCMC search,
we derived a posterior distribution of selected genes
given the observed data. Once important genes are
identiﬁed, the same logistic regression model was em-
ployed for cancer classiﬁcation. For practicality, weistic regression with Bayesian gene selection based on AIC criterion [36]
Logit-AIC
) Frequency Index No. (Clone ID)
0.1454 1008 (897781)
0.1394 496 (376516)
0.1340 336 (823940)
0.1331 2699 (44180)
0.1240 2761 (47884)
0.1167 742 (183200)
0.1044 2382 (21652)
0.1003 2018 (139354)
0.9025 157 (809981)
0.0545 739 (214068)
0.0483 1120 (841617)
0.0473 2272 (309583)
0.0472 1620 (137638)
0.0463 1999 (247818)
0.0433 1859 (307843)
0.0426 439 (160793)
0.0424 2734 (46019)
0.0419 247 (725680)
0.0414 3009 (366647)
0.0405 2423 (26082)
X. Zhou et al. / Journal of Biomedical Informatics 37 (2004) 249–259 257also investigated eﬃcient implementational issues of
these methods.
The proposed Bayesian based logit method was
tested on data sets including hereditary breast cancer
data, small round blue-cell tumor data, and acute leu-
kemia tumor data. The experimental results show that
the proposed method can eﬀectively ﬁnd genes that are
consistent with the existing biological knowledge and
with high accuracy. Our experimental results also show
that the proposed gene selection has robustness and
sensitivity properties. Note that for the breast cancer
data and acute leukemia tumor data, the classiﬁcation
accuracy of the proposed Bayesian based logit method
is much better than that reported in the original pa-
pers, and for small round blue-cell tumor data, the
proposed logit approach has a perfect classiﬁcation
result.Acknowledgment
This research was supported by the Center of Bioin-
formatics Program grant of Harvard Center of Neu-
rodegeneration and Repair, Harvard Medical School,
Boston, USA.Appendix A. Derivation of (4), (6), and (7)
For notational convenience, we denote g , r2 and
a , p2 (m  2)/3m, where m = 7.3. Since
yjbc; g;Xc NðXcbc; agImÞ;
bcjg Nð0; gRcÞ; and g  IG
m
2
;
m
2
 
;
where Rc is set as ðXTcXcÞ1 in this study, IG is the in-
verse Gamma distribution, then we have
p yjbc; g;Xc
  / am2gm2
 exp  1
2ag
ðy XcbcÞTðy XcbcÞ
 
;
ðA:1Þ
pðbcjg; cÞ / g
nc
2 jRcj
1
2 exp  1
2g
bTc ðXTcXcÞbc
 
; ðA:2Þ
pðgÞ / bðmÞg m=2þ1ð Þ exp  m
2g
 
; ðA:3Þ
where bðmÞ,ðm
2
Þm2ðCðm
2
ÞÞ1. According to the Bayesian the-
orem, we have
p bc; gjXc; y
  / p yjbc; g;Xc p bc; g 
¼ p yjbc; g;Xc
 
pðbcjgÞpðgÞ: ðA:4ÞUsing ((A.1)–(A.4)), we have
p bc; gjXc; y
  / am2gmþmþncþ22 jRcj12
 exp  1
2ag
yTy yTXcbc  Xcbc
 T
y
h
ðA:5Þ
þ Xcbc
 T
Xcbc
 þ abcR1c bci m2g

: ðA:6Þ
Deﬁne
M1c ,XTcXc þ aR1c () M c
¼ XTcXc þ aR1c
 1
; ðA:7Þ
H c,M cXTc y ¼ XTcXc þ aR1c
 1
XTc y; ðA:8Þ
P c,I XcM cXTc : ðA:9Þ
Then we have the following equations
M1c H c ¼ XTc y;
bTcX
T
c y ¼ bTcM1c H c;
yTXcH c ¼ H cM1c H c:
Note that the following equality holds:yTyyTXcbc Xcbc
 T
yþ Xcbc
 T
Xcbc
 þabcR1c bc
¼ yT IXcM cXTc
 
yþyTXcH cHTcM1c bc
bTcM1c H cþbTc XTcXcþaR1c
 
bc
¼ yTP cyþyTXcH cHTcM1c bcbTcM1c H cþbTcM cbc
¼ yTP cyþðbcH cÞTM1c ðbcH cÞ: ðA:10ÞThen (A.6) becomes
p bc;gjXc;y
 / am2gmþmþncþ22 jRj12
 exp  1
2ag
yTP cyþðbcH cÞTM1c ðbcH cÞ
h i
 m
2g
 
¼ am2gmþmþncþ22 jRj12 exp a
1yTP cyþ m
2g
 
 exp  1
2ag
ðbcH cÞTM1c ðbcH cÞ
 
: ðA:11Þ
After integrating out bc in (A.11), we have
pðgjXc; yÞ /
Z
bc
p bc; gjXc; y
 
dbc
/ amþnc2 gmþmþ22 jRcj
1
2jM cj
1
2
 exp  a
1yTP cyþ m
 
: ðA:12Þ2g
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1yTP cy
2
Þ. Hence (6) holds.
Note that
p bc; gjXc; y
  ¼ pðbcjg;Xc; yÞpðgjXc; yÞ: ðA:13Þ
Comparing (A.11), (A.12), and (A.13), we have
pðbcjg;y;XcÞ / a
nc
2 g
nc
2 jM cj
1
2
 exp  1
2ag
ðbc H cÞTM1c ðbcH cÞ
 
:
ðA:14Þ
That is bcjg; y;Xc NðH c; agM cÞ. Therefore, (7) holds.
After integrating out g in (A.12), we have
pðyjcÞ ¼
Z
g
Z
bc
pðyjbc; g;XcÞpðbcjgÞpðgÞdbc
( )
dg
/ amþnc2 jRcj
1
2jM j12
Z
g
g
mþmþ2
2
 exp  a
1yTP cyþ m
2g
 
dg
/ amþnc2 jRcj
1
2jM j12ðmþ a1yP cyÞ
mþm
2 : ðA:15Þ
We set Rc,ðXTcXcÞ1, then M c ¼ ð1þ aÞ1ðXTcXcÞ1,
and then jRcj
1
2jM cj
1
2 ¼ ð1þ aÞ
nc
2 . Hence, pðyjcÞ
/ amþnc2 ð1þ aÞ
nc
2 Sðc; yÞmþm2 , i.e., (4) holds.Appendix B. Fast computation
B.1. Computation of p(cj|y,X,ci „ j) in (8)
Because cj only takes 0 or 1, we can re-consider
p (cj = 1|y,X, i „ j) and p (cj = 0|y,X, i „ j). Let c1 =
(c1, . . . ,cj  1,cj = 1, cj + 1, . . . ,cn) and c
0 =
(c1, . . . ,cj  1,cj = 0, cj + 1, . . . ,cn). According to (8), we
have
pðcj ¼ 1jy;X ; ci6¼jÞ / a
mþn
c1
2 ð1þ aÞ
n
c1
2 Sðc1jy;XÞmþm2 pj;
pðcj ¼ 0jy;X ; ci6¼jÞ
/ a
mþn
c0
2 ð1þ aÞ
n
c0
2 Sðc0jy;XÞmþm2 ð1 pjÞ:
Since p (cj = 1|y,X,ci „ j) + p (cj = 0|y,X,ci „ j) = 1, some
straightforward computation yields
pðcj ¼ 1jy;X ; ci6¼jÞ /
1
1þ h ; ðB:1Þ
with h ¼ 1 pj
pj
ðaþ a2Þ12 Sðc
1jyXÞ
Sðc0jy;XÞ
	 
mþm
2
: ðB:2Þ
If c = c0 before cj is generated, meaning we have ob-
tained S (c0|y,X), then we only need to compute
S (c1|y,X), and vice versa.B.2. Fast computation of S(c,y) in (3)
The key to speed up the whole computation is to
compute S (c,y) fast where a gene variable is added or
removed from c. Denote
Eðc; yÞ,yTy yTXcðXTcXcÞ1XTc y: ðB:3Þ
The (B.3) can be computed using the fast QR decompo-
sition, QR-delete and QR-insert algorithms when a var-
iable is added or removed [27] (Ch. 10.1.1b). Now we
want to estimate S (c,y) in (3). After straightforward
computation, S (c,y) is given by
Sðc; yÞ ¼ mþ ay
Tyþ Eðc; yÞ
að1þ aÞ : ðB:4Þ
Thus, after computing E (c,y) using QR decomposition,
QR-delete or QR-insert algorithms, we then can obtain
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